The Motley FoolT3·4d ago
ARKG ARK Genomic Revolution ETF
ETF 48.48 DelayedETF quote, holdings, sector allocation, technicals, and options analytics. Expected move IV rank history Fibonacci levels
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
ARKG
$48.48
—
Key stats
$48.48
- 52-Week Range
- $24.60 – $58.83
- YTD
- +66.14%
- IV Rank (30D)
- 60.8
- Straddle Price
- $6.15
- P/C Vol Ratio
- 26.54
- Open
- $49.25
- Day Range
- $47.84 – $49.91
- Volume
- 2,212,001
- Prev Close
- $49.85
About
ARK Genomic Revolution ETF (ARKG) ETF
No description available.
- Exchange
- BATS
- Inception
- 2014-10-31
- Has Options
- Yes
Fund profile
holdings as of Oct 21, 2026issuer datathrough Jul 2026flows, SEC filings
- Expense ratio
- 0.75% prospectus, filed Nov 26, 2025
- Assets
- $2.1B shares × price, Oct 21, 2026
- Trailing yield
- — paid annual
- Average daily volume
- $264M 30 sessions
- Holdings
- 35 top 10 are 57.8%
- Listed
- Oct 31, 2014 Cboe BZX
Cost14
Liquidity100
Scale86
Diversification50
Moves with. Small caps over large (24% of its variance, beta 1.94); US large-cap stocks (13% of its variance, beta 0.87); Value over growth (7% of its variance, beta -0.65); Gold (4% of its variance, beta 0.17). These factors explain 49% of its daily moves over the last year.
Stated objective. The ARK Genomic Revolution ETFs (Fund) investment objective is long -term growth of capital. (from the fund's prospectus)
All 35 holdingsFlow historySimilar fundsOverlap toolAll Biotech & Health Innovation ETFs
Fund flows
through Jul 2026SEC filings- Jul 2026
- −$32M latest reported month
- Latest 3 months
- −$3.3M −0.2% of assets
- Latest 12 months
- −$1.7M −0.1% of assets
View as a table
| Month | Net flow |
|---|---|
| Jul 2026 | −$32M |
| Jun 2026 | +$136M |
| May 2026 | −$107M |
| Apr 2026 | +$60M |
| Mar 2026 | −$113M |
| Feb 2026 | +$40M |
| Jan 2026 | +$52M |
| Dec 2025 | +$9.1M |
| Nov 2025 | −$56M |
| Oct 2025 | +$95M |
| Sep 2025 | −$64M |
| Aug 2025 | −$20M |
Net creations and redemptions from the fund's SEC filings, which become public about 60 days after each quarter. Every month since 78 months ago
Similar funds
| Fund | Overlap | Fee | Assets | 1Y | |
|---|---|---|---|---|---|
| GNOMGlobal X Genomics & Biotechnology ETF | 42% | 0.50% | $110M | +54.3% | compare |
| GNMXCorgi Genomics & Precision Medicine ETF | 33% | 0.35% | $1.3M | — | compare |
| WDNAWisdomTree BioRevolution Fund | 27% | 0.45% | $2.7M | +31.0% | compare |
| ARKKARK Innovation ETF | 26% | 0.75% | $6.4B | −5.1% | compare |
| HELXFranklin Genomic Advancements ETF | 26% | 0.50% | $35M | +26.9% | compare |
Ranked by how much of the two portfolios is the same securities.
Look-through: what the holdings say
weights as of Oct 21, 2026issuer data- Holdings vs fair value
- +3.6% 33% under, 39% over · 94% covered
- Price / earnings
- — 79% loss-making · 94% covered
- Price / book · sales
- 6.2 · 11.7 revenue growth +13.5%
- Above 200-day average
- 84% 47% above 50-day · by weight
- Short interest
- 17.0% of float, weighted · 5.5 days to cover
- Insider buying
- 3% of weight had net insider buying, 90 days; 74% net selling
- 13F holders
- −2.1% change in shares held by institutions, latest quarter
- Reporting earnings
- 16.4% of weight in 7 days; 70.7% in 14
Holdings reporting in the next 14 days · weighted implied move this week 2.48%
Each figure is the fund's holdings weighted by position size, using our data on those stocks, and covers only the share of the stock holdings stated. Positive fair value means the holdings trade below our estimate.
What changed in the portfolio
Oct 20, 2026 → Oct 21, 2026| Action | Holding | Weight before | Weight after | Shares vs flows |
|---|---|---|---|---|
| Decrease | PSNLPERSONALIS INC | 1.38% | 1.03% | −23.6% |
| Increase | GOLDMAN FS TRSY OBLIG INST 468 | 0.76% | 0.95% | +28.9% |
| Increase | NTLAINTELLIA THERAPEUTICS INC | 1.70% | 1.88% | +11.4% |
0 new, 0 exited, 2 increased and 1 decreased between the fund's two latest holdings reports; turnover 1.1%. Full holdings and history
Under the hood
fiscal year to Jul 31, 2025SEC census- Authorized participants
- 14 active of 21 with agreements; top 3 did 53%
- Created · redeemed
- $1.9B · $2.1B over the fiscal year
- Redemptions in kind
- 100% creations 99% in kind
- Creation unit
- 50,000 shares
- Securities lending
- authorized, none lent
- Diversification status
- Non-diversified may concentrate in fewer issuers
From the fund's annual census filing with the SEC. In-kind redemptions are what let an ETF shed appreciated securities without realising gains.
ETF Profile
holdings as of 2026-10-21
Holdings
35
AUM
$1.9B
Provider
ARK Invest
Inception
2014-10-31
Exchange
BATS
Data As Of
2026-10-21
Expense Ratio
0.75%
Dividend Yield
—
Distribution
Annual
Recent distributions
| Ex-Date | Pay Date | Amount | Type |
|---|---|---|---|
| 2021-12-29 | 2021-12-31 | $0.3824 | CD |
Asset Allocation
Top Holdings
top 35 of 35 holdings
| Symbol | Name | Weight % | Asset Class | Country |
|---|---|---|---|---|
| TXG | 10X GENOMICS INC-CLASS A | 8.65% | Equity (US) | US |
| TWST | TWIST BIOSCIENCE CORP | 8.14% | Equity (US) | US |
| TEM | TEMPUS AI INC-CL A | 8.11% | Equity (US) | US |
| CRSP | CRISPR THERAPEUTICS AG | 5.43% | Equity (US) | US |
| NTRA | NATERA INC | 4.96% | Equity (US) | US |
| ILMN | ILLUMINA INC | 4.91% | Equity (US) | US |
| GH | GUARDANT HEALTH INC | 4.85% | Equity (US) | US |
| ABSI | ABSCI CORP | 4.75% | Equity (US) | US |
| LLY | ELI LILLY & CO | 4.15% | Equity (US) | US |
| CDNA | CAREDX INC | 3.84% | Equity (US) | US |
| BEAM | BEAM THERAPEUTICS INC | 3.49% | Equity (US) | US |
| VCYT | VERACYTE INC | 3.44% | Equity (US) | US |
| NRIX | NURIX THERAPEUTICS INC | 2.90% | Equity (US) | US |
| CMPS | COMPASS PATHWAYS PLC | 2.87% | Equity (US) | US |
| RXRX | RECURSION PHARMACEUTICALS-A | 2.76% | Equity (US) | US |
| SDGR | SCHRODINGER INC | 2.60% | Equity (US) | US |
| ADPT | ADAPTIVE BIOTECHNOLOGIES | 2.21% | Equity (US) | US |
| IONS | IONIS PHARMACEUTICALS INC | 1.96% | Equity (US) | US |
| NTLA | INTELLIA THERAPEUTICS INC | 1.88% | Equity (US) | US |
| BFLY | BUTTERFLY NETWORK INC | 1.77% | Equity (US) | US |
| WGS | GENEDX HOLDINGS CORP | 1.75% | Equity (US) | US |
| ALMR | ALAMAR BIOSCIENCES INC | 1.56% | Equity (US) | US |
| ARCT | ARCTURUS THERAPEUTICS HOLDIN | 1.53% | Equity (US) | US |
| PRME | PRIME MEDICINE INC | 1.50% | Equity (US) | US |
| MASS | 908 DEVICES INC | 1.12% | Equity (US) | US |
| PACB | PACIFIC BIOSCIENCES OF CALIF | 1.07% | Equity (US) | US |
| FRNM | FREENOME INC | 1.06% | Equity (US) | US |
| PSNL | PERSONALIS INC | 1.03% | Equity (US) | US |
| IAM | IAMBIC THERAPEUTICS INC | 1.01% | Equity (US) | US |
| GENB | GENERATE BIOMEDICINES INC | 1.00% | Equity (US) | US |
| — | GOLDMAN FS TRSY OBLIG INST 468 | 0.95% | Equity (US) | US |
| SCTX | SCRIBE THERAPEUTICS INC | 0.91% | Equity (US) | US |
| CERS | CERUS CORP | 0.88% | Equity (US) | US |
| KYMR | KYMERA THERAPEUTICS INC | 0.57% | Equity (US) | US |
| QSI | QUANTUM-SI INC | 0.40% | Equity (US) | US |
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | 9.44% | -21.44% | 22.06% | -13.08% | 9.73% | 4.28% | 1.83% |
| Feb | -10.71% | -4.69% | -12.03% | 8.47% | -7.34% | -2.09% | -4.73% |
| Mar | -9.26% | -3.31% | 0.23% | -9.07% | -10.29% | -11.67% | -7.23% |
| Apr | -0.72% | -29.21% | -2.69% | -17.85% | 8.86% | 10.26% | -5.23% |
| May | -5.48% | -9.79% | 8.32% | 2.21% | -3.82% | 14.32% | 0.96% |
| Jun | 13.78% | 1.06% | 4.70% | -6.42% | 12.52% | 21.04% | 7.78% |
| Jul | -9.16% | 11.68% | 11.86% | 16.01% | -1.45% | -9.68% | 3.21% |
| Aug | 1.44% | -2.45% | -12.93% | 1.34% | 4.92% | 19.21% | 1.92% |
| Sep | -14.11% | -7.98% | -14.57% | 1.91% | 11.98% | 15.76% | -1.17% |
| Oct | 0.32% | 1.72% | -14.58% | -6.88% | 7.90% | -9.29%* | -3.47% |
| Nov | -18.21% | -4.94% | 19.47% | 8.25% | 1.73% | -- | 1.26% |
| Dec | 1.29% | -13.70% | 13.02% | -11.78% | -2.95% | -- | -2.82% |
| Total | -37.73% | -60.91% | 13.98% | -28.23% | 32.54% | 55.57% | -4.13% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $50.88
SMA 50: $49.14
SMA 200: $36.75
Current: $48.30
EMA 12: $49.24
EMA 26: $49.60
MACD: -0.3575 | Signal: -0.4643
BULLISH
ADX (14): 21.67
WEAK TREND
+DI: 21.32
−DI: 16.24
Momentum Oscillators
RSI (14): 46.22
NEUTRAL
Stoch %K: 20.35
Stoch %D: 15.87
Williams %R: -84.75
Volume & Volatility
BB Upper: $56.29
BB Lower: $45.48
NEUTRAL
OBV: 40,678,753
Vol SMA 20: 5,334,037
Vol ROC: -61.79%
ATR: $2.30
True Range: $2.07
HV 20: 53.6%
HV 30: 53.7%
HV 60: 50.2%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-10-23T00:00:00 – 2026-10-21T00:00:00
AI Analysis
LLM Stock Analysis Report
Executive Summary
Overall Assessment: BULLISH (Confidence Level: 7/10)
Key Drivers:
- Strong momentum signals from MACD and RSI
- Positive news sentiment surrounding Cathie Wood's involvement in the stock
- Recent FDA approval for Guardant Health's blood test
Primary Risks:
- High volatility, with beta exceeding 1.94
- Potential selling pressure due to recent insider sales
Investment Thesis: ARKG presents a compelling opportunity for investors seeking exposure to biotechnology and healthcare trends. The stock's strong momentum signals and positive news sentiment outweigh the risks associated with high volatility.
Recent News Sentiment Impact: The recent FDA approval for Guardant Health's blood test has contributed to the stock's upward momentum, with positive news headlines driving investor interest.
Technical Analysis
Trend Direction:
- Short-term (1-4 weeks): Bullish
- Medium-term (1-3 months): Bullish
- Long-term (3-12 months): Neutral
Support/Resistance Levels: The SMA 20 and EMA 12 provide strong support levels at $46.70 and $47.17, respectively.
Momentum Signals:
- RSI: 57.73 (neutral)
- MACD: Bullish crossover above signal line
- Bollinger Bands: Price touching upper band = overbought
Volume Analysis: The volume rate of change is -87.19%, indicating a decline in trading activity. On-Balance Volume (OBV) remains strong, suggesting institutional interest.
News & Sentiment Analysis
Recent Headlines Summary:
- Cathie Wood's involvement in the stock has driven positive sentiment
- FDA approval for Guardant Health's blood test contributed to upward momentum
Sentiment Assessment: Positive news headlines and recent FDA approval have created a strongly positive sentiment environment.
Catalyst Identification: The upcoming earnings release (no date available) could provide additional catalysts for the stock.
Market Narrative: The positive news sentiment surrounding Cathie Wood's involvement and the recent FDA approval has driven the stock's upward momentum, aligning with the technical signals.
Risk & Volatility Assessment
Risk Metrics:
- Beta: 1.94 (high risk)
- Alpha: 0.36
- Correlation: 0.55
- Stock Volatility: 0.45
- Interpretation: High volatility - stock moves more than market
Options Market Signals: The IV rank is 10.1% (low), indicating historically low volatility. The put/call volume ratio is neutral, and the open interest suggests a relatively balanced options market.
Downside Protection: Support levels at $46.70 and $47.17 provide some downside protection.
Market Context & Positioning
Sector Performance: ARKG has outperformed the healthcare sector in recent weeks.
Institutional Activity: The on-balance volume (OBV) suggests institutional interest in the stock.
Correlation Analysis: ARKG's correlation with the healthcare sector is strong, at 0.55.
Relative Valuation: The stock is positioned within a trading range, with support levels and resistance areas established.
Key Levels & Action Items
Critical Price Levels:
- Support: $46.70 and $47.17
- Resistance: $50.98 (upper Bollinger Band)
Breakout/Breakdown Levels: A breakout above the upper Bollinger Band ($50.98) could trigger significant upward momentum.
Time-Sensitive Catalysts: The upcoming earnings release (no date available) could provide additional catalysts for the stock.
Risk Management: Stop-loss levels should be set at $44.41, and position sizing considerations suggest a relatively conservative approach.
This comprehensive analysis provides an in-depth look at ARKG's technical signals, news sentiment, and risk metrics. The bullish trend direction, positive news sentiment, and strong momentum signals outweigh the risks associated with high volatility. Investors should consider setting stop-loss levels at $44.41 and position sizing considerations to manage risk.
Generated
News
All ARKG news →
The Motley FoolT3·1mo ago
The Motley FoolT3·3mo ago
The Motley FoolT3·3mo ago
BenzingaT3·8mo ago
BenzingaT3·9mo ago
The Motley FoolT3·10mo ago
GlobeNewswire Inc.T3·19mo ago
The Motley FoolT3·21mo ago
The Motley FoolT3·26mo ago
Showing 1–10 of 50
Page 1 of 5
ARKG Options Activity & IV Rank
ARKG IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 56.0%
7-DTE IV: 63.7%
Expected Move: $6.15
7-DTE Move: $3.70
Days to Exp: 29 (2026-11-20)
Options Flow
Call Volume: 324
Put Volume: 8,600
P/C Volume: 26.543
BEARISH
Call OI: 48,673
Put OI: 71,412
P/C OI: 1.467
Total OI: 120,085
ATM Options Pricing
ATM Call: $3.35
ATM Put: $2.80
Call %: 6.9%
Put %: 5.8%
Chain Summary
Chain Volume: 31,019
Chain OI: 263,256
Last Updated: 10/22/2026
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Dealer Positioning
TYPICAL γ
Estimated net dealer gamma is at the 34th percentile of this name's own daily history, within its typical range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
34%
vs own history
GEX tilt
-0.10
OI-weighted, today
Vanna tilt
+0.44
δ-sensitivity to IV
Charm tilt
-0.56
δ-decay vs time
Vanna tilt +0.44: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt -0.56: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.
? What is this?
· 149 ATM contracts, 149k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
11%
+1.7
pts
EXTREME
ATM 59.9% / Wing 61.6%
30 DTE / 10d
23%
+3.2
pts
EXTREME
ATM 56.5% / Wing 59.7%
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)100.0HighOct 22
IV Rank (30 DTE)60.8MediumOct 22
Straddle Price (30 DTE)$6.15Oct 22
Beta Analysis
Risk Metrics
Beta: 1.8879
Alpha: 28.59%
Correlation: 0.5383
R-Squared: 29.0%
Stock Volatility: 44.7%
Market Volatility: 12.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
High volatility - stock moves more than market
Beta & Alpha Over Time
ARKG Institutional Ownership (13F)
Latest filings — 2026-09-30Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
14 filers$166.86M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $53.59M | 32.12% | 2026-06-30 |
| 2 | Jane Street Group, LLC Custodian | $35.19M | 21.09% | 2026-06-30 |
| 3 | Affinity Asset Advisors, LLC | $31.55M | 18.91% | 2026-06-30 |
| 4 | Citadel Advisors LLC Custodian | $21.56M | 12.92% | 2026-06-30 |
| 5 | Millennium Management LLC Custodian | $7.36M | 4.41% | 2026-06-30 |
| 6 | Walleye Trading LLC | $6.22M | 3.73% | 2026-06-30 |
| 7 | Barclays PLC Custodian | $3.36M | 2.02% | 2026-06-30 |
| 8 | Cubist Systematic Strategies, LLC | $3.12M | 1.87% | 2025-09-30 |
| 9 | Wolverine Trading, LLC Custodian | $2.23M | 1.34% | 2025-09-30 |
| 10 | UBS Group AG Custodian | $841.20K | 0.50% | 2026-06-30 |
| 11 | Fulcrum Equity Management | $841.20K | 0.50% | 2026-06-30 |
| 12 | Brookwood Investment Group LLC | $483.69K | 0.29% | 2026-06-30 |
| 13 | Beacon Pointe Advisors, LLC | $466.87K | 0.28% | 2026-06-30 |
| 14 | Point72 Asset Management, L.P. | $42.06K | 0.03% | 2026-06-30 |
16 filers$293.03M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Goldman Sachs Group Inc Custodian | $63.09M | 21.53% | 2026-06-30 |
| 2 | Jefferies Financial Group Inc. | $54.68M | 18.66% | 2026-06-30 |
| 3 | Susquehanna International Group, LLP Custodian | $46.73M | 15.95% | 2026-06-30 |
| 4 | 683 Capital Management, LLC | $31.55M | 10.77% | 2026-06-30 |
| 5 | Jane Street Group, LLC Custodian | $25.06M | 8.55% | 2026-06-30 |
| 6 | Millennium Management LLC Custodian | $22.46M | 7.66% | 2026-06-30 |
| 7 | Caption Management, LLC | $17.88M | 6.10% | 2026-06-30 |
| 8 | Citadel Advisors LLC Custodian | $17.64M | 6.02% | 2026-06-30 |
| 9 | Cubist Systematic Strategies, LLC | $3.25M | 1.11% | 2025-09-30 |
| 10 | NOMURA HOLDINGS INC | $2.94M | 1.00% | 2026-06-30 |
| 11 | Wolverine Trading, LLC Custodian | $2.41M | 0.82% | 2025-09-30 |
| 12 | DLD Asset Management, LP | $1.68M | 0.57% | 2026-06-30 |
| 13 | Walleye Trading LLC | $1.67M | 0.57% | 2026-06-30 |
| 14 | Point72 Asset Management, L.P. | $1.08M | 0.37% | 2026-06-30 |
| 15 | Verition Fund Management LLC | $841.20K | 0.29% | 2026-06-30 |
| 16 | STEMPOINT CAPITAL LP | $75.00K | 0.03% | 2026-06-30 |
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
21.80M
SI % of Float
52.02%
Days to Cover
4.68
Short Vol Ratio
48.9%
Free Float
—
Float %
—
Short interest 2026-09-30 • Short volume 2026-10-21
ARKG Constituent Performance
Click any bar to view the full quote for that stock.
ARKG Constituents (34 of 34)
| Symbol | Name | Weight % | Price | 1 Day | 1 Week | 1 Month |
|---|---|---|---|---|---|---|
| TXG | 10X GENOMICS INC-CLASS A | 8.65% | $69.81 | -7.65% | -3.57% | -17.01% |
| TWST | TWIST BIOSCIENCE CORP | 8.14% | $141.49 | -5.12% | -2.08% | -23.12% |
| TEM | TEMPUS AI INC-CL A | 8.11% | $65.4 | -3.48% | -8.06% | -20.48% |
| CRSP | CRISPR THERAPEUTICS AG | 5.43% | $50.19 | -0.61% | -2.58% | -9.89% |
| NTRA | NATERA INC | 4.96% | $395.04 | -4.44% | -2.41% | -3.36% |
| ILMN | ILLUMINA INC | 4.91% | $270.3 | -4.44% | +0.88% | -1.31% |
| GH | GUARDANT HEALTH INC | 4.85% | $162.42 | -2.54% | -2.09% | -7.95% |
| ABSI | ABSCI CORP | 4.75% | $9.21 | -8.27% | +3.72% | -10.97% |
| LLY | ELI LILLY & CO | 4.15% | $1319.61 | +3.84% | +5.43% | +11.65% |
| CDNA | CAREDX INC | 3.84% | $68.8 | -2.74% | +3.19% | +12.11% |
| BEAM | BEAM THERAPEUTICS INC | 3.49% | $24.63 | -0.85% | -0.40% | -0.12% |
| VCYT | VERACYTE INC | 3.44% | $46.22 | +0.00% | +4.12% | -4.78% |
| NRIX | NURIX THERAPEUTICS INC | 2.90% | $25.88 | -0.54% | +3.73% | +9.43% |
| CMPS | COMPASS PATHWAYS PLC | 2.87% | $11.66 | -1.52% | +0.34% | -10.92% |
| RXRX | RECURSION PHARMACEUTICALS-A | 2.76% | $3.57 | -1.81% | -14.08% | -8.12% |
| SDGR | SCHRODINGER INC | 2.60% | $23.01 | -3.72% | -9.69% | -21.87% |
| ADPT | ADAPTIVE BIOTECHNOLOGIES | 2.21% | $24.59 | -2.90% | -3.85% | -16.82% |
| IONS | IONIS PHARMACEUTICALS INC | 1.96% | $44.01 | -0.59% | -0.25% | +0.46% |
| NTLA | INTELLIA THERAPEUTICS INC | 1.88% | $11.41 | -2.06% | +0.62% | -6.17% |
| BFLY | BUTTERFLY NETWORK INC | 1.77% | $6.75 | -4.93% | -14.01% | -28.27% |
| WGS | GENEDX HOLDINGS CORP | 1.75% | $65.98 | -4.29% | -6.04% | -25.43% |
| ALMR | ALAMAR BIOSCIENCES INC | 1.56% | $29.39 | -6.55% | +7.18% | -11.48% |
| ARCT | ARCTURUS THERAPEUTICS HOLDIN | 1.53% | $10.85 | -1.99% | -3.73% | -23.16% |
| PRME | PRIME MEDICINE INC | 1.50% | $3.75 | -1.44% | +4.02% | +22.31% |
| MASS | 908 DEVICES INC | 1.12% | $11.47 | -2.80% | -3.53% | -0.43% |
| PACB | PACIFIC BIOSCIENCES OF CALIF | 1.07% | $2.19 | +2.38% | +11.78% | +38.66% |
| FRNM | FREENOME INC | 1.06% | $13.63 | -2.68% | +10.99% | -14.83% |
| PSNL | PERSONALIS INC | 1.03% | $15.87 | -0.22% | -0.41% | -4.25% |
| IAM | IAMBIC THERAPEUTICS INC | 1.01% | $15.2 | -3.80% | -19.62% | N/A |
| GENB | GENERATE BIOMEDICINES INC | 1.00% | $12.62 | -3.74% | -3.37% | -21.08% |
| SCTX | SCRIBE THERAPEUTICS INC | 0.91% | $17.59 | -8.86% | -15.11% | -18.60% |
| CERS | CERUS CORP | 0.88% | $2.35 | -1.46% | +4.20% | -9.77% |
| KYMR | KYMERA THERAPEUTICS INC | 0.57% | $112.7 | +0.06% | +4.22% | -2.69% |
| QSI | QUANTUM-SI INC | 0.40% | $1.19 | -3.25% | -9.16% | +51.59% |